[Clinical Value of Autoantibody Prognostic Markers in Tumor Immune Checkpoint â©Inhibitor Therapy].

Dai, Liyuan; Han, Xiaohong

[Clinical Value of Autoantibody Prognostic Markers in Tumor Immune Checkpoint â©Inhibitor Therapy].

Dai, Liyuan; Han, Xiaohong.

Afiliação

Dai L; Department of Clinical Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, â©Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100021, China.
Han X; Clinical Pharmacology Research Center, Peking Union Medical College Hospital, State Key Laboratory of Complex Severe and Rare Diseases, NMPA Key Laboratory for Clinical Research and Evaluation of Drug, Beijing Key Laboratory of Clinical PK & PD Investigation for Innovative Drugs, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.

Zhongguo Fei Ai Za Zhi ; 25(7): 534-540, 2022 Jul 20.

Article em Zh | MEDLINE | ID: mdl-35899453

Assuntos

Neoplasias Pulmonares; Neoplasias; Humanos; Inibidores de Checkpoint Imunológico; Imunoterapia/efeitos adversos; Neoplasias Pulmonares/etiologia; Neoplasias/tratamento farmacológico; Prognóstico

Palavras-chave

Autoantibody; Immune checkpoint therapy; IrAE; Prognostic marker

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Pulmonares / Neoplasias Tipo de estudo: Etiology_studies / Prognostic_studies Limite: Humans Idioma: Zh Revista: Zhongguo Fei Ai Za Zhi Assunto da revista: NEOPLASIAS Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google